Page 133 - NobleCon19revC2_Neat

MAIA Biotechnology, Inc.

SELECTED FINANCIAL ITEMS MAIA

(in millions of USD)
CQ4 '22 CQ1 '23 CQ2 '23 CQ3 '23 LTM
Income Statement Key Items
Total Revenue NA NA NA NA 0.00
Gross Profit NA NA NA NA 0.00
Gross Margin NM NM NM NM NM
EBIT (4.20) (4.18) (4.66) (4.96) (18.00)
EBIT Margin NM NM NM NM NM
Net Income to Common Shareholders (4.60) (4.12) (4.52) (4.88) (18.11)
Net Margin NM NM NM NM NM

Balance Sheet Key Items
Total Assets 12.02 9.07 10.27 7.00 7.00
Cash & Short Term Investments 10.95 7.59 9.15 6.10 6.10
% of Assets 91% 84% 89% 87% 87%
Current Assets -Total 11.81 8.33 9.78 6.63 6.63
% of Assets 98% 92% 95% 95% 95%
Total Liabilities 3.51 3.99 3.39 4.25 4.25
% of Assets 29% 44% 33% 61% 61%
Current Liabilities - Total 3.27 3.77 3.27 4.15 4.15
% of Assets 27% 42% 32% 59% 59%
Long Term Debt NA NA NA NA NA
% of Assets NM NM NM NM NM
Total Equity 8.51 5.08 6.87 2.75 2.75
% of Assets 71% 56% 67% 39% 39%

Cash Flow Statement Key Items
Net Cash Flow - Operating Activities (2.51) (3.36) (2.56) (3.16) (11.59)
Net Cash Flow - Investing NA NA NA NA 0.00
Net Cash Flow - Financing (0.63) NA 4.12 0.13 3.61

Source: Capital IQ

PRICE / VOLUME

Source: Channelchek/QuoteMedia

Noble Capital Markets' Nineteenth Annual Small & Microcap Investor Conference